These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16156938)

  • 1. Screening for oesophageal cancer: is it timely or premature?
    Baer HJ; Colditz GA
    J Med Screen; 2005; 12(3):109-11. PubMed ID: 16156938
    [No Abstract]   [Full Text] [Related]  

  • 2. Health risk appraisal models for mass screening of esophageal cancer in Japanese men.
    Yokoyama T; Yokoyama A; Kumagai Y; Omori T; Kato H; Igaki H; Tsujinaka T; Muto M; Yokoyama M; Watanabe H
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2846-54. PubMed ID: 18843030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic sensitivity and specificity and positive predictive value in the mass screening for cancer].
    Ohkawa J
    Rinsho Byori; 1988 Jul; 36(7):781-6. PubMed ID: 3236460
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry.
    Wu H; Xue R; Lu C; Deng C; Liu T; Zeng H; Wang Q; Shen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3111-7. PubMed ID: 19716777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I; Tannapfel A
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assurance of predictive markers in breast cancer.
    Rhodes A; Barnes DM
    Methods Mol Med; 2004; 97():29-57. PubMed ID: 15064483
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of predictive values of tumor markers.
    Roulston JE
    Methods Mol Med; 2004; 97():13-27. PubMed ID: 15064482
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
    Future Oncol; 2007 Apr; 3(2):127. PubMed ID: 17381411
    [No Abstract]   [Full Text] [Related]  

  • 9. Neurotrophic receptor, tropomyosin-related kinase B, as a chemoresistant marker in oesophageal cancer.
    Tanaka K; Mohri Y; Nishioka J; Ohi M; Yokoe T; Miki C; Tonouchi H; Nobori T; Kusunoki M
    Clin Oncol (R Coll Radiol); 2009 May; 21(4):362-3. PubMed ID: 19200696
    [No Abstract]   [Full Text] [Related]  

  • 10. The importance of test positive predictive value in ovarian cancer screening.
    Greene MH; Feng Z; Gail MH
    Clin Cancer Res; 2008 Nov; 14(22):7574; author reply 7577-9. PubMed ID: 18948386
    [No Abstract]   [Full Text] [Related]  

  • 11. Is an improved PSA screening test in sight?
    Savage L
    J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
    [No Abstract]   [Full Text] [Related]  

  • 12. Biomarkers of response to therapy in oesophago-gastric cancer.
    Fareed KR; Kaye P; Soomro IN; Ilyas M; Martin S; Parsons SL; Madhusudan S
    Gut; 2009 Jan; 58(1):127-43. PubMed ID: 19091831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of intramural metastases and lymph node metastases of esophageal cancer from gene expression based on boosting and projective adaptive resonance theory.
    Takahashi H; Aoyagi K; Nakanishi Y; Sasaki H; Yoshida T; Honda H
    J Biosci Bioeng; 2006 Jul; 102(1):46-52. PubMed ID: 16952836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
    Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
    Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New stool screening tests for colorectal cancer.
    Young GP; Cole S
    Digestion; 2007; 76(1):26-33. PubMed ID: 17947816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ; Zappa M; Määttänen L; Ciatto S
    Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of generalizability of sensitivity and specificity with treatment effects.
    Dodd LE; Korn EL
    Stat Med; 2008 May; 27(10):1734-44. PubMed ID: 17940996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells and aberrant methylation as tumor markers in patients with esophageal cancer.
    Ikoma D; Ichikawa D; Ueda Y; Tani N; Tomita H; Sai S; Kikuchi S; Fujiwara H; Otsuji E; Yamagishi H
    Anticancer Res; 2007; 27(1B):535-9. PubMed ID: 17348438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
    Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
    Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.